Executive Director, Global Medical Affairs
Gilead Sciences
Santa Fe, NM, United States
Joel Gallant is Executive Director of HIV Global Medical Affairs at Gilead Sciences, where he focuses primarily on HIV therapy. Before joining Gilead in 2017, he had been a professor in the Division of Infectious Diseases at Johns Hopkins University for 21 years, where he served as associate director of the HIV program. He was also a professor in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health. He subsequently directed HIV and hepatitis services and served as acting Chief Medical Officer at Southwest CARE Center in Santa Fe, New Mexico. While there he was clinical professor in the Division of Infectious Diseases at the University of New Mexico School of Medicine. He has conducted clinical trials on the treatment of HIV infection and viral hepatitis and has been an investigator in the HPTN, the Multicenter AIDS Cohort, and the ACTG.
Dr. Gallant received his M.D. at the University of California, San Francisco. He completed a residency and chief residency in internal medicine at Yale-New Haven Hospital. He received his M.P.H. at the Johns Hopkins University School of Hygiene and Public Health and completed a fellowship in infectious diseases at the Johns Hopkins University School of Medicine. He is a fellow in the IDSA and the ACP. He has served as Chair of the HIVMA and was HIVMA representative on the Board of the IDSA. He was a member of the Governing Council of the IAS and served on the Board of Directors of the IAS-USA and the ID Specialty Board of the ABIM. He was a member of the antiretroviral therapy guidelines panels of both the DHHS and the IAS-USA and also served on the IDSA/HIVMA Panel for Primary Care Guidelines for the Management of Persons Infected with HIV.
Dr. Gallant is the recipient of the 2006 HIV Clinical Educator Award from the IDSA/HIVMA. He has written and spoken extensively on HIV infection and antiretroviral therapy. Before joining Gilead, he was co-author “Medical Management of HIV Infection,” author of 100 Questions and Answers about HIV and AIDS, a book for lay readers, and editor-in-chief of the Johns Hopkins HIV Guide, a web-based educational
Disclosure(s): Gilead Sciences: Employee (Ongoing), Stocks/Bonds (Ongoing)
Wednesday, October 11, 2023
10:15 AM – 12:00 PM US ET
AE-48 - HIV Drug Resistance: Lessons from the Past and Predictions for the Future
Friday, October 13, 2023
12:15 PM – 1:00 PM US ET